Crescent Biopharma Gets FDA Clearance to Begin CR — 002 Trial
Crescent Biopharma received FDA clearance in October 2026 to begin clinical testing of CR-002, a PD-L1-targeting antibody-drug conjugate. The global Phase 1/2 APOLLO trial is scheduled to begin in fourth-quarter 2026, with initial data expected in second-half 2027. Disclaimer: This news brief was created by Public Tech